# Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

> **NCT02629796** · — · COMPLETED · sponsor: **Fondation Ophtalmologique Adolphe de Rothschild** · enrollment: 44 (actual)

## Conditions studied

- CIDP

## Interventions

- **OTHER:** CIDP treated (IVIG)

## Key facts

- **NCT ID:** NCT02629796
- **Lead sponsor:** Fondation Ophtalmologique Adolphe de Rothschild
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-16
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-11-15
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629796, "Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02629796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*